NEUROPSICOLOGÍA
![Foto de NEUROPSICOLOGÍA](/img/grupo.png)
![Foto de Pfizer (United States)](/img/noimage_org.png)
Pfizer (United States)
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de Pfizer (United States) (7)
2015
-
Disability in bipolar i disorder: The 36-item World Health Organization Disability Assessment Schedule 2.0
Journal of Affective Disorders, Vol. 174, pp. 353-360
2013
2012
-
Utility of the World Health Organization Disability Assessment Schedule II in schizophrenia
Schizophrenia Research, Vol. 138, Núm. 2-3, pp. 240-247
2011
-
Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: A comparison study between the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) and the Screen for Cognitive Impairment in Psychiatry (SCIP)
Schizophrenia Research, Vol. 130, Núm. 1-3, pp. 137-142
2010
-
Neurocognitive diagnosis and cut-off scores of the Screen for Cognitive Impairment in Psychiatry (SCIP-S)
Schizophrenia Research, Vol. 116, Núm. 2-3, pp. 243-251
2009
-
Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder
Health and Quality of Life Outcomes, Vol. 7
2008
-
Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): Psychometric properties of a brief scale for cognitive evaluation in schizophrenia
Schizophrenia Research, Vol. 99, Núm. 1-3, pp. 139-148